Serkan OCAKÇI, Seçkin ÇAĞIRGAN, MURAT TOMBULOĞLU, Güray SAYDAM

Hodgkin lenfoma ve non-hodgkin lenfoma hastalarında ESHAP ve R-ESHAP kemoterapilerinin mobilizasyon etkinliği açısından karşılaştırılması

Amaç: Geçtiğimiz yıllarda lenfomaların tedavisinde büyük ilerleme gerçekleştirilmiştir. CD20 pozitif non-Hodgkin lenfomaların tedavisinde Rituksimab altın standart olmuştur. Mobilizasyon üzerine olan etkileri üzerine yeterli çalışma yapılmamıştır. Gereç ve yöntem: 11 yıllık sürede ESHAP veya R-ESHAP ile mobilize edilmiş 84 Hodgkin lenfoma ve non-Hodgkin lenfoma hastasını değerlendirdik. Bulgular: R-ESHAP rejiminin istatistiksel olarak ESHAP rejiminden daha az etkili olmadığını bulduk. Sonuç: Aferez öncesi düşük trombosit sayısının engrafman üzerine oluşturduğu olumsuz etki ESHAP rejimine rituksimab eklenmesi ile ortadan kaldırılabilir.

A comparison of ESHAP with R-ESHAP chemotherapy regimen as mobilizing regimen in hodgkin lymphoma and non-hodgkin lymphoma patients

Objective: In recent years great advance has been succeeded in therapy of lymphomas. Rituximab has become a gold standard of CD20 positive non-Hodgkin lymphomas. Its effects on mobilization have not been studied sufficiently. Methods: We evaluated 84 Hodgkin lymphoma and non-Hodgkin lymphoma patients who were mobilized with ESHAP or R-ESHAP chemotherapy regimens in 11 years. Results: We found out that R-ESHAP regimen was not significantly inferior to ESHAP regimen. Conclusıon: Rituximab addition to ESHAP regimen may overcome negative effects of low platelet counts before aphaeresis.

PDF

___

1. Schmitz N, Haverkamp H, Josting A, et al. Long term follow up in relapsed Hodgkin’s disease (HD): updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoetic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings 2005;23: 6508.
2. Hahn T, Wolff SN, Czuczman M, et al. ASBMT Expert Panel: the role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin’s lymphoma: an evidence- based review. Biol Blood Marrow Transplant 2001;7: 308–331.
3. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapysensitive non- Hodgkin’s lymphoma. N Engl J Med 1995;333:1540– 1545.
4. Prince HM, Imrie K, Crump M, et al. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy sensitive relapsed and primary refractory non-Hodgkin’s lymphoma: identification of major prognostic groups. Br J Haematol 1996; 92: 880–889.
5. Pfreundschuh M, Rueffer U, Lathan B, et al. Dexa- BEAM in patients with Hodgkin’s disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin’s Disease Study Group. J Clin Oncol 1994;12: 580–586.
6. Martin A, Fernandez-Jimenez MC, Caballero MD, et al. Long-term follow-up in patients treated with Mini- BEAM as salvage therapy for relapsed or refractory Hodgkin’s disease. British Journal of Haematology 2001;113:161–171.
7. Alvarez I, Sureda A, Arranz R, et al. Cisplatin-Based Protocols as Salvage Therapy for Relapsed or Refractory Hodgkin’s Lymphoma Patients. ASH Annual Meeting Abstracts 2005;106:2676.
8. Moskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non- Hodgkin’s lymphoma. J Clin Oncol 1999;17: 3776- 3785.
9. Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with highdose Ara-C and dexamethasone (DHAP). Blood 1988;71: 117–122.
10. Velasquez WS, McLaughlin P, Tucker S, et al. ESHAP– an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol 1994;12: 1169–1176.
11. Girouard C, Dufresne J, Imrie K, et al. Salvage chemotherapy with mini-BEAM for relapsed or refractory non- Hodgkin’s lymphoma prior to autologous bone marrow transplantation. Ann Oncol 1997;8: 675–680.
12. Caballero MD, Amigo ML, Hernández JM, et al. Alternating mini-BEAM/ESHAP as salvage therapy for refractory non-Hodgkin’s lymphomas. Ann Hematol 1997;74: 79–82.
13. Martín A, Conde E, Arnan M, et al. Grupo Español de Linfomas/Transplante Autólogo de Médula Osea (GEL/TAMO Cooperative Group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93: 1829–36. Epub 2008 Oct 22.
14. Benekli M, Hahn T, Shafi F, et al. Effect of rituximab on peripheral blood stem cell mobilization and engraftment kinetics in non-Hodgkin’s lymphoma patients. Bone Marrow Transplant 2003; 32: 139–143.
15. Endo T, Sato N, Mogi Y, et al. Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin’s lymphoma. Bone Marrow Transplant 2004; 33: 703–707.
16. Pavone V, Gaudio F, Console G, et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation Bone Marrow Transplantation 2006; 37: 719–724.
17. Kim MK, Kim S, Lee SS, et al. Rituximab-ESHAP as a mobilization regimen for relapsed or refractory B-cell lymphomas: a comparison with ESHAP. Transfusion 2007; 47: 1447-1454.
18. Hosing C, Saliba RM, Ahlawat S, et al. Poor hematopoietic stem cell mobilizers: A single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009 Mar 12. [Epub ahead of print]
19. Mendrone A Jr, Arrais CA, Saboya R, Chamone Dde A, Dulley FL. Factors affecting hematopoietic progenitor cell mobilization: an analysis of 307 patients. Transfus Apher Sci 2008;39: 187–192.
20. Kuittinen T, Nousiainen T, Halonen P, Mahlamäki E, Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma Bone Marrow Transplant 2004;33: 907–912.